Jama Oncology最新文献

{"title":"Letters We Don't Send-A Call for Physician Condolence Letters.","authors":"Nadia Kirmani, Curtis R Chong","doi":"10.1001/jamaoncol.2026.3504","DOIUrl":"https://doi.org/10.1001/jamaoncol.2026.3504","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":20.1,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149041516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Antigen-Specific Immunotherapy a New Frontier in HPV-Initiated Head and Neck Cancer?","authors":"Kyunghee Burkitt, Barbara A Burtness","doi":"10.1001/jamaoncol.2026.3459","DOIUrl":"https://doi.org/10.1001/jamaoncol.2026.3459","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":20.1,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148992100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Symptom Trajectories and Use of Medical Assistance in Dying Among Adolescent and Young Adults With Cancer-Reply.","authors":"Miranda M Fidler-Benaoudia","doi":"10.1001/jamaoncol.2026.3758","DOIUrl":"https://doi.org/10.1001/jamaoncol.2026.3758","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":20.1,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148992105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Symptom Trajectories and Use of Medical Assistance in Dying Among Adolescent and Young Adults With Cancer.","authors":"Koichiro Yuji","doi":"10.1001/jamaoncol.2026.3755","DOIUrl":"https://doi.org/10.1001/jamaoncol.2026.3755","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":20.1,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148992071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR T-Cell Therapy in Acute Lymphoblastic Leukemia-Is Limited Persistence Enough?","authors":"Giovanna Lucchini, Giorgio Ottaviano, Andrea Biondi","doi":"10.1001/jamaoncol.2026.3016","DOIUrl":"https://doi.org/10.1001/jamaoncol.2026.3016","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":20.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148888963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.","authors":"Junjie Li, Tong Liu, Ke-Da Yu, Huawei Yang, Zhen Huang, Yi Zeng, Peng Ji, Xiaoke Hou, Chunping Liu, Yiwen Zhang, Nanlin Li, Zhong Ouyang, Xiaobo Wu, Xiaorong Bai, Yanxiang Guo, Guohui Han, Shien Cui, Zhijun Zhu, Yu Zhang, Xiaobo Hu, Xiaopeng Ma, Peifen Fu, Jinhai Zhu, Yuan Dong, Tao Wu, Hongyan Jia, Fei Xu, Yu Ren, Jianyun Nie, Dai Bing, Qiang Mu, Tao Sun, Jing Luo, Zhenchuan Song, Xiangshun Kong, Hao Zhang, Zhiyong Wu, Zhihong Wang, Dong Song, Haiquan Jia, Wei Tao, Pingming Fan, Fan Yao, Chen Ru, Guie Lai, Xin Zhou, Taolang Li, Chao Deng, Xuemei Jiang, Xiaochun Wang, Jingfen Wang, Dun Xiong, Shuqun Zhang, Hongwei Yang, Yongzhong Yao, Guobing Yin, Guangyu Yao, Li Zhou, Shu Wang, Zhigang Yu, Yang Yu, Ye Lv, Hesheng Qian, Huiping Li, Wenhui Guo, Wei Huang, Silong Xiang, Kai Zou, Hang He, Lei Fan, Zhi-Ming Shao","doi":"10.1001/jamaoncol.2026.3329","DOIUrl":"10.1001/jamaoncol.2026.3329","url":null,"abstract":"<p><strong>Importance: </strong>The combination of neoadjuvant taxanes with trastuzumab and pertuzumab remains the cornerstone treatment strategy in ERBB2-positive breast cancer. Anbenitamab (a ERBB2-biparatopic antibody that induces profound receptor clustering) and HB1801 (a solvent-free albumin-bound docetaxel), have shown promising antitumor activity and an acceptable safety profile in patients with breast cancer.</p><p><strong>Objective: </strong>To evaluate whether neoadjuvant anbenitamab combined with HB1801 could improve efficacy without increasing toxic effects for patients with early ERBB2-positive breast cancer.</p><p><strong>Design, setting, and participants: </strong>This multicenter, phase 3 registrational randomized clinical trial enrolled patients with stage II or III ERBB2-positive breast cancer from 61 hospitals in China between December 19, 2024, and August 29, 2025 (data cutoff: January 28, 2026). Data were analyzed from February 1 to March 20, 2026.</p><p><strong>Interventions: </strong>Patients were randomly assigned (1:1) to receive 6 cycles of neoadjuvant anbenitamab plus HB1801, with or without carboplatin (investigational group), or trastuzumab, pertuzumab, and docetaxel, with or without carboplatin (control group).</p><p><strong>Main outcomes and measures: </strong>The primary end point was total pathological complete response (tpCR) assessed by a blinded independent review committee.</p><p><strong>Results: </strong>Among 521 included patients (median [IQR] age, 52.0 [23-79] years), 263 were randomized to the investigational group and 258 to the control group. The tpCR rate was significantly higher in the investigational group than the control group (164 patients [62.4%] vs 132 patients [51.2%]; absolute difference, 11.4 [95% CI, 3.2 to 19.6] percentage points; P = .004). Benefit was consistent across subgroups, including subgroups with hormone receptor-positive disease (77 patients [51.7%] vs 63 patients [44.4%]), hormone receptor-negative disease (87 patients [76.3%] vs 69 patients [59.5%]), early-stage disease (111 patients [63.8%] vs 87 patients [51.8%]), locally advanced disease (53 patients [59.6%] vs 45 patients [50.0%]), with carboplatin treatment (74 patients [66.7%] vs 61 patients [54.5%]), and without carboplatin treatment (90 patients [59.2%] vs 71 patients [48.6%]). Grade 3 or 4 treatment-related adverse events occurred in 77 patients (29.3%) in the investigational group and 73 patients (28.3%) of the control group. No treatment-related deaths occurred.</p><p><strong>Conclusions and relevance: </strong>This randomized clinical trial found that neoadjuvant anbenitamab and HB1801 in patients with breast cancer significantly improved the tpCR rate compared with standard therapy with a highly manageable safety profile. This new combination may offer an improved treatment option, although long-term survival follow-up analyses are warranted.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":20.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13543038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148888883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concerns Regarding Patient Burden and Intraperitoneal Port Use in the DRAGON-01 Trial.","authors":"Yohei Kishi, Yurika Saito, Anri Inumaru","doi":"10.1001/jamaoncol.2026.3541","DOIUrl":"https://doi.org/10.1001/jamaoncol.2026.3541","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":20.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148888895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental SDHA Variant Diagnosis-A Cancer Geneticist's Viewpoint as a Patient.","authors":"Erica H Bell","doi":"10.1001/jamaoncol.2026.3316","DOIUrl":"https://doi.org/10.1001/jamaoncol.2026.3316","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":20.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148888916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concerns Regarding Patient Burden and Intraperitoneal Port Use in the DRAGON-01 Trial-Reply.","authors":"Chao Yan, Zhongyin Yang, Zhenggang Zhu","doi":"10.1001/jamaoncol.2026.3544","DOIUrl":"https://doi.org/10.1001/jamaoncol.2026.3544","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":20.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148888911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpretation of the BRIGHT-2 Trial-Reply.","authors":"Jiayu Wang, Binghe Xu","doi":"10.1001/jamaoncol.2026.2487","DOIUrl":"10.1001/jamaoncol.2026.2487","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1031-1032"},"PeriodicalIF":20.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148622256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}